REPL
NASDAQ
$11
Replimune Group Inc (REPL)
Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Hold
Target: $10.67 (-3.00%)
Market Cap
$801M
FCF 5Y CAGR
+34.46%
Free Cash Flow Yield
-35.01%
Beta (5Y)
0.74
Price Chart
Valuation
Market Cap$801M
P/B4.98
Profitability
EBITDA-$317M
EPS-$3.95
Financial Health
Debt-to-Equity50.1%
Free Cash Flow Yield-35.01%
Growth & Risk
EPS 5Y CAGR+16.21%
FCF 5Y CAGR+34.46%
Beta (5Y)0.74
Sharpe Ratio1.08